-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-10
CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for testing CDK9-dependent transcription elongation and P-TEFb-related readouts. It is appropriate for controlled biochemical, cellular, and MT4 HIV-1 propagation inhibition workflows, but not for broad-spectrum CDK inhibition or long-term storage of prepared solutions.
-
D-Luciferin Potassium Salt for ccRCC BLI
2026-09-09
D-Luciferin potassium salt converts luciferase-labeled renal cancer cells into a repeatable, non-invasive readout for tumor cell tracking and treatment response. This practical guide connects the CDCA5–DNA damage response findings in clear cell renal cell carcinoma with in vivo bioluminescence imaging, reporter assays, and assay troubleshooting.
-
MG-262: Reversible Proteasome Inhibitor Guide
2026-09-09
MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a reversible, cell-permeable boronic peptide acid that inhibits proteasome chymotryptic activity. It supports proteasome inhibition assays, apoptosis research, cell cycle arrest studies, and carefully bounded investigations of muscle proteostasis.
-
ICG001: Wnt/β-Catenin Pathway Inhibitor Guide
2026-09-08
ICG001 provides a selective way to test whether β-catenin-driven transcription depends on CBP, making it useful for mechanistic cancer and fibrosis studies. This guide translates findings from a biliary atresia liver-fibrosis study into practical assay design, dosing, controls, and troubleshooting steps.
-
Dronedarone (Multaq) in Cardiac Arrhythmia Research
2026-09-08
Dronedarone, also known as Multaq, is a multi-channel antiarrhythmic reference compound used in atrial fibrillation treatment research. The benchmark study did not identify dronedarone as an inhibitor of human KCa2.2 or KCa2.3 channels, which helps separate its established broad electrophysiology from atrial-selective KCa2 hypotheses.
-
Chemically Modified TPO mRNA Drives Thrombopoiesis
2026-09-07
The reference study shows that lipid nanoparticle-delivered, chemically modified thrombopoietin mRNA can produce biologically active TPO in mice and stimulate platelet production. Its dose-dependent pharmacodynamic effects and activity in an antibody-induced thrombocytopenia model illustrate how transient mRNA expression may provide a physiological alternative to recombinant proteins or receptor agonists.
-
Hyaluronic Acid Sodium Salt for siRNA Workflows
2026-09-05
Hyaluronic acid sodium salt, also called Sodium hyaluronate, is a high-molecular-weight extracellular matrix component with mechanical and signaling functions. Its most defensible nanoparticle application is as a hyaluronic acid coating in a preclinical siRNA platform, not as proof that free polymer alone treats infection.
-
PFPD Nanorods for DNA Damage and STING Activation
2026-09-05
The reference study develops nuclear-targeted peptide nanorods that co-deliver the photosensitizer PpIX and the STING agonist DMXAA, using localized photodynamic DNA damage to amplify innate antitumor immunity. Its findings connect subcellular drug delivery with cGAS/STING activation, NK- and T-cell responses, and suppression of lung metastatic tumors, while also highlighting the translational constraints of light-dependent nanotherapy.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-04
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines immune challenges with pharmacological metabolism modulation and cytokine measurement. Its main contribution is a scalable ex vivo framework for resolving how anabolic and catabolic pathways selectively shape immune responses while preserving the cellular complexity of whole blood.
-
MDL 28170: A Causal Calpain Assay Strategy
2026-09-04
MDL 28170 is a cell-permeable calpain inhibitor that helps researchers test whether excessive cysteine protease activity drives synaptic, neuronal, or stress-related phenotypes. This article develops an assay-centered framework grounded in maternal-surgery neurodevelopment research, with emphasis on specificity, target engagement, and interpretation.
-
Bacitracin (B1670): Practical Lab Workflow
2026-09-03
Bacitracin (B1670) is a dossier-defined peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. It should be used in validated laboratory assays only, not for diagnostic, clinical, or medical applications.
-
Compartment-Specific Contractility in Intestinal Epithelium
2026-09-03
Hinnant, Ning, and Lechler used compartment-restricted genetic activation of myosin activity to show that intestinal villi and crypts respond to contractility in fundamentally different ways. Villar contractility altered cell shape and remotely stimulated crypt proliferation, whereas crypt contractility deformed nuclei, induced DNA damage, and triggered apoptosis, revealing long-range mechanical regulation along the crypt–villus axis.
-
HSP90–METTL3 Control of MYC m6A in Colorectal Cancer
2026-09-02
The reference study identifies METTL3 as an HSP90 client protein and shows that 17-AAG-driven HSP90 inhibition promotes CHIP-mediated METTL3 degradation, reducing m6A modification and stability of MYC mRNA in colorectal cancer. Its integrated protein, RNA, and functional assays support the HSP90–METTL3–MYC axis as a mechanistically grounded, although not yet clinically validated, therapeutic framework.
-
Resazurin Sodium Salt in iPSC Drug Testing
2026-09-02
Resazurin sodium salt can add a scalable metabolic viability layer to complex iPSC disease models, but its signal should be interpreted as a redox-dependent proxy rather than a standalone measure of cell number or disease correction. This thought-leadership guide connects assay mechanism, workflow design, and translational decision-making for CF and other demanding cell models.
-
CYP51 Mutations and DMI Resistance in Cercospora beticola
2026-09-01
Isaac Terrance Courneya’s 2024 North Dakota State University thesis examines how synonymous and nonsynonymous CbCyp51 haplotypes relate to demethylation inhibitor resistance in Cercospora beticola. By combining RT-qPCR expression analysis with engineered haplotype-replacement strains, the study separates expression-associated patterns from genetic effects while also revealing substantial confounding from the transformation process.